Udabage Lishanthi, Brownlee Gary R, Stern Robert, Brown Tracey J
Laboratory for Hyaluronan Research, Department of Biochemistry and Molecular Biology, Monash University, Wellington Road, Clayton, Victoria, 3800 Australia.
Glycoconj J. 2004;20(7-8):461-71. doi: 10.1023/B:GLYC.0000038292.71098.35.
The concentration and molecular weight of hyaluronan often dictates its physiological function. Consequently full characterisation of the anabolic products and turnover rates of HA could facilitate understanding of the role that HA metabolism plays in disease processes. In order to achieve this it is necessary to interrupt the dynamic balance between concurrent HA synthesis and degradation, achievable through the inhibition of the hyaluronidases, a group of enzymes which degrade HA. The sulphated polysaccharide, dextran sulphate has been demonstrated to competitively inhibit testicular hyaluronidase in a non-biological system, but its application to in vitro biological systems had yet to be developed and evaluated. This study determined the inhibitory concentrations of dextran sulphate against both testicular and Streptomyces hyaluronidase in a cell-free and breast cancer model followed by characterisation of the effect that hyaluronidase inhibition exerted on HA synthesis and degradation. The IC(100) of dextran sulphate for both hyaluronidases in a cell-free and biological system was determined to be >or=400 microg/ml. At concentrations up to 10 mg/ml the dextran sulphate did not effect breast cancer cell proliferation or morphology, while at 400 microg/ml HA degradation was totally inhibited, enabling an accurate quantitation of HA production as well as characterisation of the cell-associated and liberated HA. FACS quantitation of the HA receptor CD44, HA synthase and the hyaluronidases HYAL 1 and HYAL 2 demonstrated that dextran sulphate down-regulated CD44 and HA synthase while upregulating the hyaluronidases. These results suggest dynamic feedback signalling and complex mechanisms occur in the net deposition of HA in vivo.
透明质酸的浓度和分子量常常决定其生理功能。因此,对透明质酸合成产物及转换率进行全面表征,有助于理解透明质酸代谢在疾病过程中所起的作用。为实现这一点,有必要打破透明质酸合成与降解之间的动态平衡,这可通过抑制透明质酸酶来实现,透明质酸酶是一类可降解透明质酸的酶。硫酸化多糖硫酸葡聚糖已被证实在非生物系统中可竞争性抑制睾丸透明质酸酶,但其在体外生物系统中的应用尚未得到开发和评估。本研究测定了硫酸葡聚糖在无细胞和乳腺癌模型中对睾丸及链霉菌透明质酸酶的抑制浓度,随后对透明质酸酶抑制作用对透明质酸合成和降解的影响进行了表征。在无细胞和生物系统中,硫酸葡聚糖对两种透明质酸酶的IC(100)均被确定为≥400μg/ml。在浓度高达10mg/ml时,硫酸葡聚糖对乳腺癌细胞增殖或形态无影响,而在400μg/ml时,透明质酸降解被完全抑制,从而能够准确定量透明质酸的产生以及对细胞相关和释放的透明质酸进行表征。对透明质酸受体CD44、透明质酸合酶以及透明质酸酶HYAL 1和HYAL 2进行流式细胞术定量分析表明,硫酸葡聚糖下调了CD44和透明质酸合酶,同时上调了透明质酸酶。这些结果表明,在体内透明质酸的净沉积过程中存在动态反馈信号和复杂机制。